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ABSTRACT
Objective: We applied marginal structural models (MSMs) to estimate the
effects of medication adherence with hypoglycemics on reducing the risk
of microvascular complications in type 2 diabetic patients.
Methods: A retrospective longitudinal cohort study for type 2 diabetes
patients was conducted using the California Medicaid claims database
(1995–2002). Medication adherence and multiple time-varying confound-
ers were measured quarterly over a maximum of 7.5 years follow-up. Cox
regression models and MSMs results on the effect of compliance were
compared.
Results: Of 4708 eligible patients, 2644 (56.2%) experienced microvas-
cular complications during the follow-up period. After controlling for
baseline covariates, standard Cox models estimated that adherence was
associated with increased risk of complication with hazard ratio (HR) of
1.09 (95% conﬁdence interval (CI): 1.00, 1.18). With adjustment of
time-varying confounders as exogenous variables, the HR was 0.96 (0.88,
1.04). Using the MSM technique, the HR was 0.76 (95% bootstrap CI:
0.60, 0.92), indicating a signiﬁcant beneﬁt of medication adherence with
hypoglycemics on the reduction of microvascular complications. This
result contrasts with the negative results obtained in the hazard model, and
is more consistent with prior clinical trial results
Conclusion: Unlike conventional models, MSMs estimated that higher
medication adherence may result in reduced risk of microvascular com-
plications among patients with type 2 diabetes.
Keywords: adherence, marginal structural models, medication compli-
ance, persistence, type 2 diabetes.
Introduction
The ultimate goal of medication adherence research is to improve
health outcomes in target populations. Nevertheless, the effect of
medication adherence on health outcomes and the magnitude of
such effects have not been rigorously studied. Although the ran-
domized clinical trial is the gold standard for causal inference,
medication adherence (synonym of “compliance” [1]) is a patient
subjective choice, and cannot be randomly assigned. Therefore,
researchers need to use observational studies to understand such
relationships.
DiMatteo et al. conducted a meta-analysis on the relationship
between adherence and health outcomes, and only identiﬁed 44
articles pertaining to medication adherence [2]. They noted that
one reason for such underinvestigation of this important rela-
tionship in the literature is that the beneﬁt of adherence on
outcomes was often taken for granted. In addition, they found
that “the studies . . . are all correlational” [2], which reﬂects the
limitations of conventional methodology in addressing the rela-
tionship between adherence and outcomes.
In an observational study, the estimation of the relationship
between medication compliance and outcomes can be con-
founded by selection bias, where patients with more severe
disease tend to be more adherent to medication, perhaps due to
a perception of greater need [3]. In addition, medication treat-
ment for chronic illness is not a static intervention but a pro-
longed and dynamic process that may vary over time where
perceived improvement in treatment outcomes may reduce or
increase future adherence. Given the presence of time-varying
confounding, reviewers of the compliance literature have cast
doubt on whether the effect of compliance could be identiﬁed. As
Morris and Schulz noted, “researchers have attempted to identify
causal relationships between variables, assuming that the vari-
ables can be treated as independent. Nevertheless, the phenom-
enon of medication-taking behavior involves variables that are
interrelated with the possibility of feed-back loops” [4]. This
time-varying confounding phenomenon is also recognized by
DiMatteo et al., as “reverse causality,” which “may play a
role . . . , particularly during a long course of treatment” [2].
Time-varying confounding is a ubiquitous phenomenon in
health intervention research. Nevertheless, conventional studies
often assume adherence as constant, and measure it using a single
index over the study period (e.g., Medication Possession
Ratio—MPR), whereas the outcomes are also frequently mea-
sured during the same study period. The partial correlation
between adherence and outcomes is then established by control-
ling baseline covariates. Because of the ambiguous temporal
order and their mutual interaction, the effect of adherence on
outcomes and the effect of outcomes on adherence cannot be
distinguished. Furthermore, the effects of both time-independent
and time-varying confounding could produce biased and puz-
zling estimates. Therefore, because of the limitations of the tra-
ditional study design, lack of methodological rigor [5], and
publication bias, the assumption that adherence is beneﬁcial to
health outcomes remains unproven [2,6].
Despite lack of convincing evidence, it is commonly taken for
granted that higher medication adherence improves outcomes
[2], and it is frequently quoted: “drugs don’t work in patients
who don’t take them.” Yet it is important to understand whether
higher adherence improves outcomes and the extent of it,
because it is the rationale behind adherence-improving
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interventions and disease management programs, as well as a key
element of cost-effectiveness modeling for estimating effective-
ness under real-world adherence. This study hypothesizes that
higher adherence improves outcomes and an alternative model is
proposed to estimate these effects.
In contrast to the conventional model, this study measures
both adherence and other outcomes-related covariates (time-
varying confounders) repeatedly over time, and accounts for the
dynamic interactive effects between adherence and time-varying
confounders. This estimation method is executed by applying
marginal structural models (MSMs), which is a relatively new
model design developed by Robins and colleagues [7,8].
Robins and colleagues developed MSMs for causal inference
of time-varying treatment in observational longitudinal studies
with the presence of time-varying confounding effect [8–10].
These models operate under the assumption of sequential ignor-
ability, i.e., there is no unmeasured confounder conditional on
past treatment and covariate history. MSMs are estimated using
inverse probability of treatment weight (IPTW), where the
inverse probabilities of receiving the actual treatment given a set
of previous covariate history are served as weights (with further
stabilization) to estimate the effect of treatment [8,11,12]. As an
intuitive interpretation, at any speciﬁc time, the purpose of
weighting is to create a pseudo-population where time-varying
confounders no longer predict adherence level at time; therefore,
the confounding effects are removed with weighting and the
effect estimate of compliance remains unchanged. Thus, an oth-
erwise complicated model can be converted to a traditional Cox
proportional hazards model with the application of patient- and
time-speciﬁc weights.
The IPTW estimation method used in MSMs is an extension
of the propensity score method to a longitudinal model (i.e., a
longitudinal version of the propensity score method), where pro-
pensity scores were not only estimated and applied at baseline (as
in traditional method), but also estimated and applied at each
time intervals. In contrast to the conventional approach that
assumes that the initial treatment decision is intended over the
entire follow-up period, this longitudinal MSM assumes treat-
ment decisions are allowed to change over time conditional on
the past treatment response. In this study, the time-varying pro-
pensity score (i.e., “probability of treatment”) refers to the prob-
ability of choosing higher adherence level conditioning on
baseline and time-varying confounders. After applying inverse
weighting of the time-varying propensity scores, the treatment of
choice would be random, with the assumption of no unmeasured
confounders at each point in time (i.e., sequential ignorability).
The principal objective of this study is to estimate the effect of
adherence to hypoglycemic medications on preventing microvas-
cular complications (e.g., retinopathy, neuropathy, and nephr-
opathy) among type 2 diabetes patients. A secondary goal of this
study is to demonstrate the merit of MSMs when estimating the
effect of medication adherence on health outcomes in a longitu-
dinal setting, by comparing it to conventional regression
methods.
Methods
Data
The data source for this study is a random 20% extract of the
fee-for-service portion of the California Medicaid program
(Medi-Cal) paid claims and eligibility ﬁles from 1995 to 2002.
Medi-Cal covers outpatient care, nursing home, inpatient, pre-
scription drugs, as well as other medical services for poor and
disabled California residents. Medi-Cal paid claims ﬁles include
institutional (facility) claims at the claim level, professional ser-
vices by speciﬁc service, and pharmacy claims for each ﬁlled
prescription. Eligibility ﬁles include the monthly-recorded enroll-
ment status and enrollees’ demographic information.
Sample Selection
The study cohort includes adult type 2 diabetic patients (identi-
ﬁed by International Statistical Classiﬁcation of Diseases and
Related Health Problems (ICD)-9-CM: 250.xx, but with no.
250.x1 or 250.x3 in claims history) who newly started on
hypoglycemic medications with a minimum prior period of 6
months with no hypoglycemic prescriptions. The date of the ﬁrst
hypoglycemic prescription ﬁlled serves as the index date. In addi-
tion, selected patients were required to have at least two pre-
scription ﬁlls of hypoglycemics (either oral hypoglycemics or
insulin), and continuous enrollment from 6 months before to 12
months after the index date. Figure 1 provides a diagram of the
study timeline.
Patients were excluded if they initiated insulin as the only
hypoglycemic during the ﬁrst quarter after the index date (which
is very rare among type 2 diabetes patients). Patients were also
excluded if they had a diagnosis of diabetes-related microvascu-
lar complications in the preindex period or within 3 months after
the index date, because many patients may have experienced
complications at the time of starting medication treatment [13].
This exclusion was justiﬁed because patients with concurrent
complications appear to have a different response to medications
[14,15].
The ﬁnal selected patient cohort was followed until the ﬁrst
occurrence of any of the following events: 1) disenrollment from
Medi-Cal; 2) diagnosis of diabetes-related microvascular compli-
cations [16]; and 3) the end of data availability (i.e., 12/2002).
Outcomes Measure
Outcome was deﬁned as the time span from the index date to the
ﬁrst diagnosis of diabetic microvascular complications in any
Figure 1 Diagram of study time line. Rx: hypoglycemic prescription.
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medical claim, including neurological disorders, diabetic foot
problems, retinopathy, and nephropathy [16].
Adherence and Covariates
Adherence is measured quarterly using the MPR, the ratio of
total number of days covered by any prescription of hypogly-
cemic class within a given quarter over the number of calendar
days (90 days). When the days supplied from prescription ﬁlls
of the same class overlap each other, the overlapped coverage
days are not double counted when calculating MPR for this
class. MPRs of the different classes of hypoglycemic medications
ﬁlled within a quarter are averaged to be the MPR for that
quarter. For comparison to traditional analyses, two versions of
a single-index MPR measure were generated: a ﬁxed-length
single index MPR (adherence over 1 year) and variable-length
single index MPR (adherence over the entire follow-up period
up to the event occurrence or censoring point deﬁned by aver-
aging MPRs of all followed quarters). Adherence level is
dichotomized based on a traditional threshold of an 80% MPR
value [2,17,18]. Sensitivity analyses of different thresholds for
the adherence deﬁnition were conducted with 10% point incre-
ments from 40% to 90%.
Patient-speciﬁc baseline variables included age in years at
index date, gender, ethnicity (Asian, Black, Hispanic, Caucasian,
and other), index year (calendar year of the index date), length of
preindex eligibility in months, Charlson Comorbidity Index mea-
sured over the 6-month preindex period, and hypoglycemic
regimen during the ﬁrst quarter after the index date. Regimens
with relatively high frequency are reported, and the rest are
combined together as “other regimens.”
The following covariates were measured quarterly as time-
varying confounders considering their potential interaction effect
with adherence: 1) number of ofﬁce/outpatient visits; 2) any
emergency visit (dichotomous); 3) any hospitalization (dichoto-
mous); 4) number of unique drugs measured at generic active
ingredient combination level regardless whether the drug is dia-
betes related or not; 5) any use of self-monitoring blood glucose
monitors (SMBG), lancets and test strips use (as identiﬁed by
Healthcare Common Procedure Coding System codes, Medi-Cal
supply codes, or national drug code codes as recorded in Medi-
Cal paid claims); 6) any diagnosis of hypoglycemia; 7) any diag-
nosis of coronary heart disease (CHD), congestive heart failure
(CHF), depression, hypertension, dyslipidemia, valvular disease,
obesity, or hypothyroidism; 8) any use of ACE inhibitors (ACEI)
or angiotensin receptor blockers; 9) any diagnosis of uncon-
trolled status of diabetes (250.x2); and 10) any diagnosis of
ketoacidosis or hyperosmolarity.
Descriptive Analysis
Patient baseline characteristics and their initial hypoglycemic
regimens are described with mean and standard deviation for
continuous variables and number and percentage for categorical
variables. The Wilcoxon test is reported for comparing continu-
ous variables, and the chi square test for categorical variables.
Cox Proportional Hazard Models
We ﬁrst applied the conventional methodology to estimate effect
of adherence. The Cox proportional hazard model is a semipara-
metric model with time-invariant proportionality assumption. To
show the different modeling strategies with alterative speciﬁca-
tions of Cox models and MSMs, we constructed ﬁve models with
increasingly weaker assumptions (see Fig. 2). Model 1 includes a
ﬁxed-length single-index adherence variable C without any other
covariates, which is the overall adherence measure for the ﬁrst
year. Model 2 includes two models with baseline covariates B
and two measures of adherence: ﬁxed-length single-index adher-
ence and variable-length single-index adherence. Model 3
includes baseline covariates B and time-varying adherence C(t)
which was measured each quarter until the end of the follow-up
period. Model 4 includes baseline covariates B, all time-varying
covariates L(t), and time-varying adherence measure C(t). In
model 4, time-varying covariates were entered as exogenous
variables (not determined by past treatment history) and their
dynamic interactions with time-varying adherence were ignored.
Lastly, model 5 was an MSM with IPTW estimation which
modeled time-varying covariates as confounders independent of
time-varying adherence.
MSMs
In order to implement the MSMs, we ﬁtted weighted pooled
logistic regressions with each person-quarter as an observation
for weight estimation [8]. To obtain more robust error estimates,
we performed nonparametric bootstraps of random sampling
with replacement of 500 times to estimate 95% conﬁdence inter-
val (CI) of adherence effect on outcomes. All analyses were
performed by SAS version 9.1 (SAS Institute Inc., Cary, NC,
2003).
Results
Patient Characteristics
A total of 4708 patients with type 2 diabetes were selected as our
study cohort, with an average 8.9 and median 6.4 quarters of
follow-up. These patients contributed a total of 44,464 patient-
quarter observations. The mean age was 61.0 (14.8) years, and
40.0% were male (Table 1). At baseline, 21.2% of the patients
had a record of diagnosis for hypertension, 6.7% with dyslipi-
demia, 7.1% with CHD, and 3.6% with CHF. During the ﬁrst
quarter, 2544 (54.0%) patients received sulfonylurea mono-
therapy (SUL) and 1190 (25.3%) received metformin mono-
therapy (MET). Sulfonylureas plus metformin (SUL + MET) was
the predominant combination therapy used as the initial therapy
by 520 (11.1%) patients. By the end of the follow-up period,
2644 (56.2%) patients had received at least one diagnosis of
microvascular complications, and the median complication-free
survival time was seven quarters.
Adherence Changes over Time
For the entire 44,464 included patient-quarters, the mean of
MPR of all quarters was 48.4% (39.1%) and the median was
54.4%. The distribution was not normal, with 13,500 (30.4%)
of the quarters having zero MPR, corresponding to no drug-
covered days during the quarter, and 4028 (9.5%) quarters
having 100% MPR. To examine the longitudinal adherence
pattern, we ﬁrst plotted the population adherence over time using
a box plot to summarize mean, median, and interquartile range
for each quarter (available upon request). The adherence patterns
appeared to be smooth and stable at the population level over
time despite of a sharp drop during the ﬁrst year. Nevertheless,
the population mean did not provide insights regarding indi-
vidual changes over time in adherence. Figure 3 depicts the
plotted quarterly measured MPRs of 10 randomly selected
patients revealing an erratic pattern of patients’ longitudinal
adherence.
Survival Analysis and Cox Regression Models
Without adjustment of any covariate in model 1, the 1-year
single-index adherence was associated with higher risk (hazard
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ratio, HR = 1.08) of developing at least one microvascular
complication, with statistical signiﬁcance of P = 0.092 (Table 2).
When adjusting for baseline covariates with Cox regression
model in model 2A, the 1-year single index adherence was still
associated with higher risk (HR = 1.06), but as with model 1, the
adherence variable was not statistically signiﬁcant. model 2B is
the same as model 2A, except that a variable-length single-index
measure of adherence over the entire follow-up period is used.
The estimated HR of this adherence measure was 1.53
(P < 0.0001), presenting a very strong detrimental effect of
higher adherence. Model 3 included time-varying adherence
measured quarterly up to the end of the follow-up period with
baseline covariates, and estimated the HR of adherence as
1.09 with statistical signiﬁcance (P = 0.0449). Including all
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Figure 2 Diagrams of study models with (increasingly weaker) assumptions required for unbiased estimates. C, single-index adherence; B, baseline covariates; C(t),
time-varying adherence; L(t), other time-varying covariates; U, unobservable factors;Y, the outcome variable. Model 1: random clinical trial; Model 2–4: Cox models
with different assumptions; Model 5: MSM (with weakest assumption).
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time-varying covariates in model 4, the selection bias appeared to
be alleviated, with estimates indicating a trivial effect of adher-
ence (HR = 0.96, P = 0.3089).
Adherence Effects Estimated by MSM with IPTW
Combining all patient quarters, the mean of the stabilized
weights was 1.37 (SD = 19.57) and median 0.812 (interquartile
range = 0.592-1.070). Summarizing the weights by quarter, the
box plot shows the temporal distribution of the log of stabilized
weights (Fig. 4). This plot shows that the mean stabilized weights
are decreasing over time, yet being “stable” and not too far from
the zero line, and the variation of stabilized weights increases
over time.
Applying the estimated stabilized weights, the effect of adher-
ence on the risk of microvascular onset was estimated by gener-
alized estimating equations (GEE) with binomial distribution and
logit link function. The estimated hazard risk was 0.73 (Table 2),
with a bootstrap 95% CI (0.60, 0.92), showing a statically
signiﬁcant beneﬁt of adherence. The CI estimated by the robust
estimator of standard error of GEE as (0.54, 0.99) and P-value of
0.0441, which is more conservative. This estimate illustrates a
reasonable effect estimate by addressing time-varying confound-
ing. Comparing all estimates using different methods, only the
adherence effect estimated by MSMs indicates a beneﬁcial effect
of adherence on outcomes, whereas all other estimates indicate
that improved adherence is associated with increased risk of
developing microvascular complications.
Sensitivity Analysis
We repeated the analysis for all speciﬁed modeling strategies
(model 1–5) by various MPR thresholds using 10% point incre-
ments from 40% to 90%. The results of the estimated HRs of
adherence (not reported here) reveal that the beneﬁt of adherence
estimated by MSMs is stable across different adherence cutoff
points, with the effects more pronounced at smaller threshold
values (e.g., 40% and 50%).
Discussion
Past efforts of investigating the relationship between adherence
and outcomes often establish an associational relationship using
conventional models. Because patients who experience worse
intermediate outcomes over time tend to increase the subsequent
drug adherence, relative sickness and adherence tend to be posi-
tively correlated and vary over time. Therefore, conventional
regression models without appropriate accounting for dynamic
interaction between time-varying adherence and intermediate
variables are prone to negative effects of higher medication
adherence, as evidenced in models 1 to 4 in this study. This could
partially explain the relative scarcity of publication in estimating
the effect of adherence level on outcomes, despite the voluminous
literature in other aspects of medication adherence (e.g., measur-
ing, predicting, or developing methods to improve adherence).
Since 1975, over 32,000 articles were classiﬁed under the medical
subject heading “patient compliance,” yet the beneﬁt of
higher medication adherence on health outcomes remains an
assumption.
In contrast with past research, this study applied a longitudi-
nal MSM that accounted for time-varying confounding, and
demonstrated that hypoglycemic adherence signiﬁcantly reduced
the risk of microvascular complications (HR = 0.73, 95% boot-
strap CI: 0.60, 0.92). It should be noted that this result is con-
sistent with the United Kingdom Prospective Diabetes Study
(UKPDS) clinical trial ﬁndings that glycemic control by SULs or
insulin compared to a conventional diet reduced microvascular
complications [19].
There are several elements of this study that require further
exploration in subsequent studies. We dichotomized adherence
partially for the analytical and interpretational convenience when
MSMs were applied, althoughMSMs can also be used to estimate
the effect of multilevel categorical or continuous exposure vari-
ables. Althoughwe applied sensitivity analysis to test the impact of
different thresholds on dichotomizing adherence, future studies
with ﬁner levels of adherence may be needed to explore the
nonlinear effect of adherence on outcomes. In addition, the MSM
estimate is based on the weaker assumption that the treatment
decision is independent of unobserved confounders at each time
conditional on the past observed covariates and intermediate
outcomes. Despite controlling multiple observed time-varying
confounders,many parameters are unobservable or immeasurable
because of the limitations of administrative claims databases. For
example, it would be preferable to have speciﬁc clinical and
Table 1 Baseline characteristics of the study population (n = 4708)
Variable
Mean SD
n (%)
Age 61.0 14.8
Male 1882 (40.0)
Race
Asian 1261 (26.8)
Black 434 (9.2)
Hispanic 637 (13.5)
Other 881 (18.7)
Caucasian 1495 (31.8)
Index year
1995 571 (12.1)
1996 1009 (21.4)
1997 616 (13.1)
1998 530 (11.3)
1999 525 (11.2)
2000 673 (14.3)
2001 784 (16.7)
Prior eligibility length in quarter 28.3 20.9
Charlson comorbidity index at baseline 1.1 1.1
Number of different drugs 4.2 3.8
Number of ofﬁce/outpatient visits 2.2 3.4
Comorbidities at baseline
CHD 336 (7.1)
CHF 169 (3.6)
Depression 88 (1.9)
Hypertension 997 (21.2)
Dyslipidemia 314 (6.7)
Valvular Disease 62 (1.3)
Obesity 85 (1.8)
Hypothyroidism 66 (1.4)
Initial hypoglycemics regimen
SUL 2544 (54.0)
MET 1190 (25.3)
SUL +MET 520 (11.1)
TZD 97 (2.1)
INS + SUL 48 (1.0)
INS +MET 43 (0.9)
SUL + TZD 45 (1.0)
MET + TZD 40 (0.9)
NAT 32 (0.7)
All Other 149 (3.2)
Other time-varying covariates at baseline
Any ER visit 184 (3.9)
Any hospitalization 501 (10.6)
Use of ACEI or ARB 869 (18.5)
Uncontrolled diabetic condition 269 (5.7)
Hypoglycemia 57 (1.2)
Ketoacidosis or hyperosmolarity 43 (0.9)
SD, standard deviation; CHD, coronary heart disease; CHF, congestive heart failure; SUL,
sulfonylureas; MET, metformin;ACEI,ACE inhibitors;ARB, angiotensin receptor blockers.
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behavior factors such as fasting blood glucose, hemoglobin A1c
(HbA1c), blood pressure, lipid level, body weight, diet, and
exercise over time. These parameters also change andmay interact
with adherence over time, and thus may be considered as time-
varying confounders. Future studies of this nature should incor-
porate such measures. Finally, it should be noted that the study
outcomes are based on presence of an ICD-9 diagnosis code of
microvascular complications. The timing of such microvascular
complications is unknown, and patients with microvascular com-
plications may be undiagnosed until long after their onset.
Additionally, this study evidenced a strong beneﬁcial effect of
adherence to medication, but it provides no insight regarding the
mechanisms by which medication adherence produces this effect.
The effect could be partially owing to the therapeutic effect of the
drug therapy, and can also contain the psychological effect of
belief about the drug (e.g., the placebo effect, or the effect of
positive thinking) that is independent of the therapeutic effect. In
addition, the estimated effect could include the beneﬁt of adher-
ence to other behavioral modiﬁcations, such as diet, exercise,
self-care of eye/foot, adherence to SMBG, and even better com-
pliance to ofﬁce appointments, which collectively may account
for a major portion of the overall estimated beneﬁt. These effects
could be largely immeasurable and inseparable to that of medi-
cation adherence, even in a well-controlled setting. Nevertheless,
this composite effect of multiple inseparable components, albeit
labeled as “adherence effect,” may be more meaningful than a
therapeutic effect alone in real practice. For example, patient
education programs aimed at improving overall patient adher-
ence to healthy behaviors could simultaneously improve medica-
tion adherence and positive beliefs about drug efﬁcacy.
Longitudinal data, where treatment and other factors inﬂu-
encing treatment decision change over time, provide a rich source
of information. This study addressed an important question in
medication adherence research that is complicated by the
Figure 3 Quarterly adherence of 10 randomly selected patients. MPR, medicine possession ratio.
Table 2 Comparison of adherence effect estimates of model 1–5
Model no. Model Estimate Hazard ratio 95% CI P-value
1 C1 0.0737 1.08 (0.99, 1.17) 0.0923
2A C1 + B 0.0532 1.06 (0.97, 1.15) 0.235
2B C2 + B 0.4266 1.53 (1.40, 1.67) <0.0001
3 C(t) + B 0.0851 1.09 (1.00, 1.18) 0.0449
4 C(t) + B + L(t) -0.0447 0.96 (0.88, 1.04) 0.3089
5 MSM -0.3151 0.73 (0.54, 0.99) 0.0441
(Bootstrap) (0.60, 0.92)
Notes: No. 1—a Cox model only including ﬁxed length single index adherence C1,No. 2A—a Cox model including ﬁxed length single index adherence C1 and baseline covariate(s) B, No. 2B—a
Cox model including variable length single index adherence C1 and baseline covariate(s) B,No. 3—a Cox model including time-varying adherence and baseline covariate(s) B,No. 4—a Cox model
including time-varying adherence and time-varying covariate(s) L(t), No. 5—a Marginal structural model with IPTW estimation and Bootstrap estimation for conﬁdence interval.
MSM, marginal structural model; IPTW, inverse probability of treatment weight.
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dynamic interactions between time-varying adherence and con-
founders. Unlike conventional research methods correlating
adherence level and outcomes, the MSM with time-varying
confounding demonstrated a signiﬁcantly beneﬁcial effect of
higher medication adherence on the risk of developing microvas-
cular complication in type 2 diabetes.
Medication adherence is predicated on the expectation that
patients make individual choices in treatment decision-making
and self-select the adherence level after trading off multiple
factors such as perceived clinical beneﬁt, side effects, and cost
[20,21]. Strategies intended to enhance adherence have been
found to be surprisingly weak in their effects, as even the most
effective interventions had only modest effects on adherence and
outcomes [22,23]. Understanding the relationship between
adherence and clinically important outcomes, and the factors
that moderate the relationship between adherence and these out-
comes, may guide future evaluations of interventions designed to
improve adherence [2].
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authors have no conﬂicts of interest which are relevant to the contents of
this manuscript. The manuscript was prepared without a contract or
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